Tenfold dose reduction of the in vivo cancer-destroying dose of TNF using combination therapies with PI3K inhibitors or NKT activators
(2009) 100th annual meeting of the American Association for Cancer Research (AACR) — Location: Denver, CO, USA (18.April.2009)
